[Probably] because of the recession and since clean tech investments are still sizzling hot these days, Oncolin Therapeutics is having a big makeover from being a drug development company to becoming a renewable energy producer through its subsidiary New EnerSource.Oncolin Therapeutics recently ditched 75% of its ownership in its biotech subsidiary Intertech Bio as the company does not have enough green dough to fund an early stage biotech company.
No comments:
Post a Comment